Mathilde Cabart

1.1k total citations
21 papers, 253 citations indexed

About

Mathilde Cabart is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Mathilde Cabart has authored 21 papers receiving a total of 253 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Mathilde Cabart's work include Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Mathilde Cabart is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Mathilde Cabart collaborates with scholars based in France, United States and Italy. Mathilde Cabart's co-authors include Guilhem Roubaud, Paul Sargos, Isabelle Soubeyran, Nicolas Sévenet, Sophie Cousin, François Chomy, Florent Peyraud, Vittorio Catena, Jean‐Philippe Guégan and Xavier Buy and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Mathilde Cabart

17 papers receiving 251 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mathilde Cabart France	9	127	127	75	32	28	21	253
Stephanie P.L. Saw Singapore	6	166 1.3×	138 1.1×	68 0.9×	26 0.8×	25 0.9×	14	278
Silvana Acquafredda Italy	6	94 0.7×	159 1.3×	42 0.6×	24 0.8×	43 1.5×	8	237
Enrico Caliman Italy	9	81 0.6×	145 1.1×	60 0.8×	22 0.7×	20 0.7×	24	219
David Vicente Baz Spain	10	138 1.1×	173 1.4×	52 0.7×	17 0.5×	40 1.4×	27	235
Koji Fukase Japan	10	77 0.6×	150 1.2×	102 1.4×	91 2.8×	23 0.8×	28	289
Valeria Smiroldo Italy	10	85 0.7×	199 1.6×	70 0.9×	51 1.6×	11 0.4×	28	280
Loïck Galland France	11	80 0.6×	181 1.4×	61 0.8×	11 0.3×	48 1.7×	25	298
Carlos Mayo United States	9	151 1.2×	164 1.3×	75 1.0×	28 0.9×	18 0.6×	16	254
Beili Gao China	10	106 0.8×	135 1.1×	122 1.6×	22 0.7×	22 0.8×	24	278
M. Naomi Horiba United States	7	45 0.4×	93 0.7×	78 1.0×	49 1.5×	13 0.5×	12	186

Countries citing papers authored by Mathilde Cabart

Since Specialization

Citations

This map shows the geographic impact of Mathilde Cabart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mathilde Cabart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mathilde Cabart more than expected).

Fields of papers citing papers by Mathilde Cabart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mathilde Cabart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mathilde Cabart. The network helps show where Mathilde Cabart may publish in the future.

Co-authorship network of co-authors of Mathilde Cabart

This figure shows the co-authorship network connecting the top 25 collaborators of Mathilde Cabart. A scholar is included among the top collaborators of Mathilde Cabart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mathilde Cabart. Mathilde Cabart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grellety, Thomas, Carine Bellera, Coralie Cantarel, et al.. (2025). Important aspects of care and priorities of older patients with cancer: The PRIORITY multicenter cohort study. Journal of Geriatric Oncology. 102812–102812.

Cabart, Mathilde, Loı̈c Mourey, Sophie C. Schneider, et al.. (2024). Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database. Journal of Geriatric Oncology. 15(7). 101819–101819.

Roubaud, Guilhem, et al.. (2024). A randomized, non-comparative, phase II multicentric trial on short-term darolutamide (ODM-201) concomitant to radiation therapy for patients with unfavorable intermediate-risk prostate cancer: DARIUS (AFU-GETUG P15).. Journal of Clinical Oncology. 42(4_suppl). TPS349–TPS349.

Barthélémy, Philippe, Yohann Loriot, Constance Thibault, et al.. (2024). Updated results from AVENANCE: Real-world effectiveness of avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) and analysis of subsequent treatment.. Journal of Clinical Oncology. 42(4_suppl). 561–561. 13 indexed citations

Bessede, Alban, Florent Peyraud, Sylvestre Le Moulec, et al.. (2023). Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non–Small Cell Lung Cancer. Clinical Cancer Research. 29(23). 4883–4893. 12 indexed citations

Bessede, Alban, Florent Peyraud, Benjamin Besse, et al.. (2023). TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 30(4). 779–785. 20 indexed citations

Italiano, Antoîne, Laura Leroy, Jean‐Philippe Guégan, et al.. (2023). TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.. Journal of Clinical Oncology. 41(16_suppl). 9040–9040. 2 indexed citations

Mathoulin‐Pélissier, Simone, H. Charitansky, Yann Godbert, et al.. (2023). Evaluating video-based consultations in routine clinical practice at a comprehensive cancer center. Acta Oncologica. 62(12). 1905–1912. 1 indexed citations

Bessede, Alban, Aurélien Marabelle, Jean‐Philippe Guégan, et al.. (2022). Impact of acetaminophen on the efficacy of immunotherapy in cancer patients. Annals of Oncology. 33(9). 909–915. 28 indexed citations

10.

Cabart, Mathilde, et al.. (2022). 1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 33. S1334–S1334. 1 indexed citations

11.

Brouste, Véronique, et al.. (2022). Impact of 18 FDG- PET CT in the Management of Muscle Invasive Bladder Cancer. Clinical Genitourinary Cancer. 20(3). 297–297.e6. 10 indexed citations

12.

Greillier, Laurent, Éléna Paillaud, Nicolas Girard, et al.. (2022). Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF). Cancers. 14(3). 769–769. 7 indexed citations

13.

Peyraud, Florent, Jean‐Philippe Guégan, Sophie Cousin, et al.. (2022). Identification of super-exhausted T cells: A novel population predictive of response to immunotherapy.. Journal of Clinical Oncology. 40(16_suppl). 2596–2596. 2 indexed citations

14.

Soubeyran, Pierre, Yann Godbert, Mathilde Cabart, et al.. (2021). 1613P What are the barriers to routine clinical use of teleconsultation in oncology? A retrospective study on patient’s and their physician’s satisfaction with 603 video teleconsultations. Annals of Oncology. 32. S1150–S1150.

15.

Palussière, Jean, Sophie Cousin, Mathilde Cabart, et al.. (2021). Is There a Role for Percutaneous Ablation for Early Stage Lung Cancer? What Is the Evidence?. Current Oncology Reports. 23(7). 81–81. 14 indexed citations

16.

Cabart, Mathilde, et al.. (2021). Prostate cancer and PARP inhibitors: progress and challenges. Journal of Hematology & Oncology. 14(1). 51–51. 97 indexed citations

17.

Procureur, Adrien, Loïc Verlingue, Francesco Facchinetti, et al.. (2021). 711P Outcomes according to genomic characteristics of patients with metastatic urothelial carcinoma in phase I/II trials. Annals of Oncology. 32. S718–S719. 1 indexed citations

18.

Raimbourg, Judith, Marie‐Pierre Joalland, Mathilde Cabart, et al.. (2017). Sensitization of EGFR Wild-Type Non–Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib. Molecular Cancer Therapeutics. 16(8). 1634–1644. 17 indexed citations

19.

Cabart, Mathilde, Jean‐Sébastien Frenel, L. Campion, et al.. (2016). Le statut KRAS n’influence pas l’efficacité de l’oxaliplatine ou de l’irinotécan, en association au bévacizumab, dans le traitement de première ligne du cancer colorectal métastatique. Bulletin du Cancer. 103(6). 541–551. 4 indexed citations

20.

Cabart, Mathilde, Jean‐Sébastien Frenel, L. Campion, et al.. (2016). Bevacizumab Efficacy Is Influenced by Primary Tumor Resection in First-Line Treatment of Metastatic Colorectal Cancer in a Retrospective Multicenter Study. Clinical Colorectal Cancer. 15(4). e165–e174. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact